<p>Milestone Pharmaceuticals（纳斯达克代码：MIST - 获取免费报告）在周一发布给投资者的研究报告中，被 TD Cowen 的股票研究人员从 “持有” 评级上调至 “买入” 评级。该券商目前对该股票的目标价为 8.00 美元。TD Cowen 的目标价暗示该股票相较于之前的收盘价有 239.70% 的潜在上涨空间。</p>
<p>MIST 还受到其他几份报告的关注。Weiss Ratings 在 12 月 1 日的报告中重申了对 Milestone Pharmaceuticals 股票的 “卖出（e+）” 评级。Wells Fargo &amp; Company 在 9 月 11 日的研究报告中开始覆盖 Milestone Pharmaceuticals，给予 “增持” 评级和 4.00 美元的目标价。最后，Wall Street Zen 在周六的报告中将 Milestone Pharmaceuticals 的股票评级从 “持有” 下调至 “卖出”。三位分析师给予该股票 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “持有”，共识目标价为 5.67 美元。</p>
<p><strong>查看我们最新的 MIST 股票报告</strong></p>
<h2>Milestone Pharmaceuticals 股价下跌 2.3%</h2>
<p>周一，MIST 股票下跌 0.06 美元，报 2.36 美元。该公司的股票交易量为 42,738,590 股，而其平均交易量为 2,079,424 股。该公司的市值为 2.0058 亿美元，市盈率为-2.79，贝塔值为 0.40。该公司的 50 日简单移动平均为 2.18 美元，200 日简单移动平均为 1.91 美元。Milestone Pharmaceuticals 的 12 个月低点为 0.63 美元，12 个月高点为 3.06 美元。该公司的债务与股本比率为 2.74，速动比率为 8.24，流动比率为 8.24。</p>
<p>Milestone Pharmaceuticals（纳斯达克代码：MIST - 获取免费报告）最近在 11 月 12 日发布了季度财报。该公司报告的每股收益为-0.12 美元，超出市场共识预期的-0.17 美元，超出幅度为 0.05 美元。整体来看，研究分析师预测 Milestone Pharmaceuticals 在当前年度的每股收益为-0.62 美元。</p>
<h2>机构投资者对 Milestone Pharmaceuticals 的看法</h2>
<p>几家对冲基金和其他机构投资者最近调整了对 MIST 的持仓。Propel Bio Management LLC 在第三季度将其在 Milestone Pharmaceuticals 的持仓增加了 186.1%。Propel Bio Management LLC 目前拥有 5,124,890 股该公司股票，价值 10,250,000 美元，此前在上个季度又购买了 3,333,333 股。Orbimed Advisors LLC 在第三季度购买了 Milestone Pharmaceuticals 的新头寸，价值约为 6,444,000 美元。Simplify Asset Management Inc.在第三季度将其在 Milestone Pharmaceuticals 的持仓增加了 186.2%。Simplify Asset Management Inc.目前拥有 2,832,974 股该公司股票，价值 5,666,000 美元，此前在上个季度又收购了 1,842,974 股。Pathstone Holdings LLC 在第三季度购买了 Milestone Pharmaceuticals 的新股份，价值约为 2,000,000 美元。最后，Boxer Capital Management LLC 在第三季度购买了 Milestone Pharmaceuticals 的新头寸，价值约为 1,333,000 美元。目前 86.18% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Milestone Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Milestone Pharmaceuticals Inc 是一家生物制药公司，专注于心血管药物的开发和商业化。该公司的主要产品候选药物是 etripamil，一种新型且有效的钙通道阻滞剂，目前正在美国和加拿大进行治疗阵发性室上性心动过速的第三阶段临床试验；并在进行治疗房颤和快速心室率的第二阶段临床试验。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Milestone Pharmaceuticals</li>
<li>罗素 2000 指数，投资者如何利用它进行盈利交易</li>
<li>三家公司将大现金流转化为更大的股东收益</li>
<li>什么是分红成就者？简介</li>
<li>GOOGL 的不可阻挡的势头推动价格目标创下新高</li>
<li>现在购买的三只沃伦·巴菲特股票</li>
<li>三只被低估的机器人股票，准备迎来巨额收益</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUlTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUlTVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Milestone Pharmaceuticals 吗？</h2>
<p>在你考虑 Milestone Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Milestone Pharmaceuticals 并不在名单上。</p>
<p>虽然 Milestone Pharmaceuticals 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

MIST

<p>TD Cowen 将 Milestone Pharmaceuticals（NASDAQ:MIST）的评级从 “持有” 上调至 “买入”，设定目标价为 8.00 美元，暗示上涨空间为 239.70%。尽管其他分析师的评级不一，该股票的共识评级为 “持有”，目标价为 5.67 美元。机构投资者显著增加了持股。Milestone 专注于心血管药物，其主要产品 etripamil 正在进行临床试验。该股票下跌 2.3%，报 2.36 美元，市值为 2.0058 亿美元</p>

<p>Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) was upgraded by equities researchers at TD Cowen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note issued to investors on Monday. The brokerage currently has a $8.00 target price on the stock. TD Cowen's price target suggests a potential upside of 239.70% from the stock's previous close.</p>
<div class="lb-trans"><p>Milestone Pharmaceuticals（纳斯达克代码：MIST - 获取免费报告）在周一发布给投资者的研究报告中，被 TD Cowen 的股票研究人员从 “持有” 评级上调至 “买入” 评级。该券商目前对该股票的目标价为 8.00 美元。TD Cowen 的目标价暗示该股票相较于之前的收盘价有 239.70% 的潜在上涨空间。</p>
</div><p>MIST has been the subject of several other reports. Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Milestone Pharmaceuticals in a report on Monday, December 1st. Wells Fargo &amp; Company initiated coverage on Milestone Pharmaceuticals in a research note on Thursday, September 11th. They issued an &#34;overweight&#34; rating and a $4.00 price target on the stock. Finally, Wall Street Zen lowered shares of Milestone Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of &#34;Hold&#34; and a consensus price target of $5.67.</p>
<div class="lb-trans"><p>MIST 还受到其他几份报告的关注。Weiss Ratings 在 12 月 1 日的报告中重申了对 Milestone Pharmaceuticals 股票的 “卖出（e+）” 评级。Wells Fargo &amp; Company 在 9 月 11 日的研究报告中开始覆盖 Milestone Pharmaceuticals，给予 “增持” 评级和 4.00 美元的目标价。最后，Wall Street Zen 在周六的报告中将 Milestone Pharmaceuticals 的股票评级从 “持有” 下调至 “卖出”。三位分析师给予该股票 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “持有”，共识目标价为 5.67 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on MIST</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 MIST 股票报告</strong></p>
</div><h2>Milestone Pharmaceuticals Trading Down 2.3%</h2>
<div class="lb-trans"><h2>Milestone Pharmaceuticals 股价下跌 2.3%</h2>
</div><p>MIST stock traded down $0.06 on Monday, reaching $2.36. The company's stock had a trading volume of 42,738,590 shares, compared to its average volume of 2,079,424. The firm has a market cap of $200.58 million, a PE ratio of -2.79 and a beta of 0.40. The business has a fifty day simple moving average of $2.18 and a two-hundred day simple moving average of $1.91. Milestone Pharmaceuticals has a 12-month low of $0.63 and a 12-month high of $3.06. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24.</p>
<div class="lb-trans"><p>周一，MIST 股票下跌 0.06 美元，报 2.36 美元。该公司的股票交易量为 42,738,590 股，而其平均交易量为 2,079,424 股。该公司的市值为 2.0058 亿美元，市盈率为-2.79，贝塔值为 0.40。该公司的 50 日简单移动平均为 2.18 美元，200 日简单移动平均为 1.91 美元。Milestone Pharmaceuticals 的 12 个月低点为 0.63 美元，12 个月高点为 3.06 美元。该公司的债务与股本比率为 2.74，速动比率为 8.24，流动比率为 8.24。</p>
</div><p>Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.05. As a group, research analysts forecast that Milestone Pharmaceuticals will post -0.62 EPS for the current year.</p>
<div class="lb-trans"><p>Milestone Pharmaceuticals（纳斯达克代码：MIST - 获取免费报告）最近在 11 月 12 日发布了季度财报。该公司报告的每股收益为-0.12 美元，超出市场共识预期的-0.17 美元，超出幅度为 0.05 美元。整体来看，研究分析师预测 Milestone Pharmaceuticals 在当前年度的每股收益为-0.62 美元。</p>
</div><h2>Institutional Investors Weigh In On Milestone Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Milestone Pharmaceuticals 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of MIST. Propel Bio Management LLC lifted its position in Milestone Pharmaceuticals by 186.1% during the third quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company's stock valued at $10,250,000 after purchasing an additional 3,333,333 shares in the last quarter. Orbimed Advisors LLC bought a new position in shares of Milestone Pharmaceuticals during the 3rd quarter valued at approximately $6,444,000. Simplify Asset Management Inc. increased its holdings in Milestone Pharmaceuticals by 186.2% in the 3rd quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company's stock worth $5,666,000 after acquiring an additional 1,842,974 shares in the last quarter. Pathstone Holdings LLC bought a new stake in Milestone Pharmaceuticals during the 3rd quarter worth approximately $2,000,000. Finally, Boxer Capital Management LLC purchased a new position in Milestone Pharmaceuticals during the third quarter valued at approximately $1,333,000. 86.18% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近调整了对 MIST 的持仓。Propel Bio Management LLC 在第三季度将其在 Milestone Pharmaceuticals 的持仓增加了 186.1%。Propel Bio Management LLC 目前拥有 5,124,890 股该公司股票，价值 10,250,000 美元，此前在上个季度又购买了 3,333,333 股。Orbimed Advisors LLC 在第三季度购买了 Milestone Pharmaceuticals 的新头寸，价值约为 6,444,000 美元。Simplify Asset Management Inc.在第三季度将其在 Milestone Pharmaceuticals 的持仓增加了 186.2%。Simplify Asset Management Inc.目前拥有 2,832,974 股该公司股票，价值 5,666,000 美元，此前在上个季度又收购了 1,842,974 股。Pathstone Holdings LLC 在第三季度购买了 Milestone Pharmaceuticals 的新股份，价值约为 2,000,000 美元。最后，Boxer Capital Management LLC 在第三季度购买了 Milestone Pharmaceuticals 的新头寸，价值约为 1,333,000 美元。目前 86.18% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Milestone Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Milestone Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.</p>
<div class="lb-trans"><p>Milestone Pharmaceuticals Inc 是一家生物制药公司，专注于心血管药物的开发和商业化。该公司的主要产品候选药物是 etripamil，一种新型且有效的钙通道阻滞剂，目前正在美国和加拿大进行治疗阵发性室上性心动过速的第三阶段临床试验；并在进行治疗房颤和快速心室率的第二阶段临床试验。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Milestone Pharmaceuticals</li>
<li>Russell 2000 Index, How Investors Use it For Profitable Trading</li>
<li>3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains</li>
<li>What Are Dividend Achievers? An Introduction</li>
<li>GOOGL's Unstoppable Momentum Drives Price Targets to Record Highs</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>3 Underrated Robotics Stocks Poised for Huge Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Milestone Pharmaceuticals</li>
<li>罗素 2000 指数，投资者如何利用它进行盈利交易</li>
<li>三家公司将大现金流转化为更大的股东收益</li>
<li>什么是分红成就者？简介</li>
<li>GOOGL 的不可阻挡的势头推动价格目标创下新高</li>
<li>现在购买的三只沃伦·巴菲特股票</li>
<li>三只被低估的机器人股票，准备迎来巨额收益</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUlTVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=MIST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Milestone Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Milestone Pharmaceuticals 吗？</h2>
</div><p>Before you consider Milestone Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Milestone Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Milestone Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Milestone Pharmaceuticals 并不在名单上。</p>
</div><p>While Milestone Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Milestone Pharmaceuticals 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Milestone Pharmaceuticals（纳斯达克代码：MIST）在 TD Cowen 被上调至买入评级